Robert O. Dillman

Allergan (Ireland) — Ireland

Immunology and Microbiology · Life Sciences

41h-index8.1kcitations323works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(143), CAR-T cell therapy research(85), Cancer Immunotherapy and Biomarkers(83), Monoclonal and Polyclonal Antibodies Research(62), Cancer Research and Treatments(51)

Publications322 total

A review of vaccinology and <i>ex vivo</i> antigen-loaded dendritic cells: A different approach to infectious disease vaccines
Human Vaccines & Immunotherapeutics·2025Open Access
Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer
Vaccines·2025Open Access
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival
Human Vaccines & Immunotherapeutics·2025· 3 citedOpen Access
Abstract 651: Safety and efficacy of pembrolizumab plus personal dendritic cell vaccines in elderly patients with metastatic melanoma
Cancer Research·2025
Abstract B118: Manufacturing patient-specific autologous dendritic cell vaccines targeting antigens from autologous tumor cells that were self-renewing in liquid cell culture and injecting such vaccines to treat patients with advanced cancer
Cancer Immunology Research·2025
Abstract 6519: Dendritic cell vaccine cell numbers and survival in patients with primary glioblastoma
Cancer Research·2024
Next-generation vaccines are showing promise against glioblastoma
Oncotarget·2024Open Access
1411 Feasibility, safety, and efficacy of personal vaccines consisting of autologous dendritic cells loaded <i>ex vivo</i> with autologous tumor antigens from self-renewing cancer cells
Regular and Young Investigator Award Abstracts·2023Open Access
Treatment-related adverse events in a randomized trial in stage three and four ovarian cancer testing patient-specific dendritic cell vaccines loaded with tumor antigens from self-renewing autologous tumor cells (1258)
Gynecologic Oncology·2023
Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.
Journal of Clinical Oncology·2023
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
Journal of Clinical Oncology·2023· 3 cited
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
Human Vaccines & Immunotherapeutics·2023· 19 citedOpen Access
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Journal of Experimental & Clinical Cancer Research·2022· 46 citedOpen Access
562 Tumor collection and establishment of tumor-initiating cell cultures to serve as the antigen source for AV-OVA-1 dendritic cell vaccines for patients with newly diagnosed advanced ovarian cancer
Regular and Young Investigator Award Abstracts·2022Open Access
565 Leukapheresis to obtain monocytes to produce dendritic cells for manufacturing AV-OVA-1 personal vaccines in a randomized phase II trial in patients with newly diagnosed advanced ovarian cancer
Regular and Young Investigator Award Abstracts·2022Open Access
Phase 2 Study of AV-GBM-1 (a Tumor-initiating Cell Targeted Dendritic Cell Vaccine) in Newly Diagnosed Glioblastoma Patients: Safety and Efficacy Assessment
Research Square (Research Square)·2022· 1 citedOpen Access
Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma
Journal of Oncology Research and Therapy·2022· 2 citedOpen Access
A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses
Human Vaccines & Immunotherapeutics·2022· 10 citedOpen Access
Abstract CT571: Plasma proteomic markers prognostic or predictive for survival of patients with newly diagnosed glioblastoma who were treated in a phase II trial with standard care and the addition of the novel patient-specific dendritic cell vaccine AV-GBM-1
Cancer Research·2022
Seizures as treatment-emergent adverse events during glioblastoma clinical trials.
Journal of Clinical Oncology·2022
page 1 of 17Next →

Frequent Co-authors

Carol DePriest(9), Daniel L. Shawler(8), Neil M. Barth(8), Patric M. Schiltz(7), Linda D. Beutel(7), Cristina de Leon(6), Shankar K. Nayak(5), Ivor Royston(4), Samuel E. Halpern(4), Christopher Duma(4), Andrew N. Cornforth(4), Edward F. McClay(4), Senthamil R. Selvan(4), Richard M. Bartholomew(3), Robert K. Oldham(3), Robert Birch(3), Duane E. Johnson(3), James M. Frincke(3), Stephen L. Seagren(2), Michael C. Perry(2)